54 active not recruiting, 43 completed, 36 recruiting, 8 terminated. 98 Phase 2, 48 Phase 1, 21 Phase 3, 2 Not applicable, 2 Phase 4.
Follow acalabrutinib: new trials by email Literature Review of acalabrutinib trials Research Report on acalabrutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-10-23 |
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study Acalabrutinib, Rituximab, Glofitamab - Phase 2 Study, MCL | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-04-01 | 2026-05-20 |
| A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma Rocbrutinib, Ibrutinib, Acalabrutinib - Mantle Cell Lymphoma | Phase 3 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 394 | 2026-02-05 | 2026-02-06 |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia Sonrotoclax, Zanubrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 500 | 2026-01-22 | 2026-09-28 |
| Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies Zanubrutinib, Acalabrutinib - Chronic B-cell Malignancies, BTK Inhibitors | Not yet recruiting | University Hospital, Caen | 15000 | 2025-12-22 | 2025-12-16 | |
| Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL Venetoclax, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Zulfa Omer | 62 | 2025-12-05 | 2026-01-06 |
| Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy Venetoclax combined with Ibrutinib, Venetoclax combined with Zanubrutinib, Venetoclax combined with Acalabrutinib - Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 79 | 2025-12-01 | 2025-11-25 |
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | VA Office of Research and Development | 100 | 2025-10-01 | 2025-10-14 |
| A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy - Mantle-cell Lymphoma | Phase 2 | Recruiting | AstraZeneca | 55 | 2025-09-05 | 2026-10-02 |
| A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Pirtobrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Withdrawn | AstraZeneca | 2025-06-30 | 2025-06-05 | |
| Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Seema Bhat | 61 | 2025-05-27 | 2025-12-16 |
| Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma Acalabrutinib, Rituximab - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 50 | 2025-04-14 | 2025-06-03 |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure Acalabrutinib, Investigator's choice of treatment - Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment | Phase 4 | Recruiting | AstraZeneca | 60 | 2025-02-04 | 2026-09-24 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-09-08 |
| Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL Polatuzumab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 152 | 2024-12-31 | 2024-06-04 |
| Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 40 | 2024-12-02 | 2026-01-05 |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Venetoclax, Acalabrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | AbbVie | 170 | 2024-08-05 | 2026-04-09 |
| Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies BTK inhibitor (Ibrutinib or Acalabrutinib) - Chronic B-cell Malignancies, BTK Inhibitors | Unknown | University Hospital, Caen | 15000 | 2024-07-25 | 2024-08-21 |
Showing 20 of 155. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (55) · Lymphoma, Mantle-Cell (31) · Lymphoma, Large B-Cell, Diffuse (17) · Lymphoma, Non-Hodgkin (15) · Lymphoma (11) · Leukemia, B-Cell (7) · COVID-19 (6) · Leukemia (5) · Lymphoma, B-Cell (5) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Waldenstrom Macroglobulinemia (4) · Multiple Myeloma (3) · Burkitt Lymphoma (2) · Cardiovascular Diseases (2)
Acerta Pharma BV (41) · AstraZeneca (21) · M.D. Anderson Cancer Center (10) · City of Hope Medical Center (5) · German CLL Study Group (3) · Dana-Farber Cancer Institute (2) · Fred Hutchinson Cancer Center (2) · Inhye Ahn (2) · Mayo Clinic (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University Hospital Southampton NHS Foundation Trust (2) · University Hospital, Caen (2) · Washington University School of Medicine (2) · Weill Medical College of Cornell University (2) · AbbVie (1)
United States (111) · United Kingdom (29) · Spain (23) · Italy (22) · Poland (20) · France (19) · Germany (19) · Australia (18) · Brazil (14) · Canada (14) · China (14) · Czechia (13) · South Korea (12) · Taiwan (12) · Belgium (11)
Priti Patel, MD (3) · Inhye Ahn, MD (2) · A. Kater (1) · Adalberto Ibatici (1) · Adel Habib, MD (1) · Aditi Saha, M.D. (1) · Agostino Tafuri (1) · Ahmed Hamdy, MD (1) · Ajay Gopal (1)
PMID 39563886, PMID 34534514, PMID 36695483, PMID 40461100, PMID 26641137, PMID 27601462, PMID 28714866, PMID 29241979, PMID 31088809, PMID 31866281, PMID 31876911, PMID 31915195, PMID 32054731, PMID 32114502, PMID 32202637, PMID 32305093, PMID 32459600, PMID 33206936, PMID 33709202, PMID 33730844, PMID 33796237, PMID 34269152, PMID 34310172, PMID 34350582, PMID 34398557, PMID 34608724, PMID 34735860, PMID 35594173, PMID 35952327, PMID 35988545, PMID 36102212, PMID 36377973, PMID 36442911, PMID 36689726, PMID 37183115, PMID 37227160, PMID 37273420, PMID 37384412, PMID 37390310, PMID 37497921, PMID 38393694, PMID 38555311, PMID 38557285, PMID 38598745, PMID 38620072, PMID 38754046, PMID 38781315, PMID 38952054, PMID 39271521, PMID 39319495
2023 (13), 2014 (6), P30CA033572 (5), 2019 (4), 2015 (3), 2016 (1), 2017 (1), 2018 (1), 2025 (1), P30CA015083 (1), P30CA138292 (1), R01CA266298 (1), U10CA180820 (1)